Showing results (31-40 of 150) with videos related to
Sort By:
Pageof 15
Bulletin Du Cancer|May 1, 1994
[Value of rhodamine 123 in the detection of minor amounts of multidrug resistant cells]M Maynadié, G Lizard, E Solary, et al.Leukemia|November 14, 2013
The Ten-Eleven Translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseasesE Solary, O A Bernard, A Tefferi, et al.Anticancer Research|November 1, 1994
Multidrug resistance phenotype evaluation by immunofluorescence and functional tests: comparison of two monoclonal antibodies and three fluorescent dyes in three cells linesM Maynadie, G Lizard, E Solary, et al.Journal of the National Cancer Institute|June 4, 1997
Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicityO Micheau, E Solary, A Hammann, et al.Pathologie-Biologie|May 1, 1987
[Treatment of bacterial infections by ofloxacin. 42 cases]P Chavanet, S Arnould, Y Sarret, et al.Cancer Genetics and Cytogenetics|May 1, 1992
New case of t(3;17)(q26;q22) as an additional change in a Philadelphia-positive chronic myelogenous leukemia in accelerationF Mugneret, E Solary, B Favre, et al.European Journal of Haematology|May 1, 1992
Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemiaL Campos, D Guyotat, C Jaffar, et al.Oncogene|April 21, 2001
Modulation of apoptosis by procaspase-2 short isoform: selective inhibition of chromatin condensation, apoptotic body formation and phosphatidylserine externalizationN Droin, C Rébé, F Bichat, et al.International Journal of Cancer|July 10, 1999
FAS(CD95) ligand expression by tumor cell variants can be unrelated to their capacity to induce tolerance or immune rejectionN Favre, B Bonnotte, N Droin, et al.International Journal of Cancer|July 1, 1994
Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistanceE Solary, Y H Ling, R Perez-Soler, et al.Pageof 15